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Abstract
Introduction: Hyperuricemia is the greatest risk factor for gout and is caused by an overproduction and/or
inefficient renal clearance of urate. The fractional renal clearance of urate (FCU, renal clearance of urate/renal
clearance of creatinine) has been proposed as a tool to identify subjects who manifest inefficient clearance of
urate. The aim of the present studies was to validate the measurement of FCU by using spot-urine samples as a
reliable indicator of the efficiency of the kidney to remove urate and to explore its distribution in healthy subjects
and gouty patients.
Methods: Timed (spot, 2-hour, 4-hour, 6-hour, 12-hour, and 24-hour) urine collections were used to derive FCU in
12 healthy subjects. FCUs from spot-urine samples were then determined in 13 healthy subjects twice a day,
repeated on 3 nonconsecutive days. The effect of allopurinol, probenecid, and the combination on FCU was
explored in 11 healthy subjects. FCU was determined in 36 patients with gout being treated with allopurinol. The
distribution of FCU was examined in 118 healthy subjects and compared with that from the 36 patients with gout.
Results: No substantive or statistically significant differences were observed between the FCUs derived from spot
and 24-hour urine collections. Coefficients of variation (CVs) were both 28%. No significant variation in the spot
FCU was obtained either within or between days, with mean intrasubject CV of 16.4%. FCU increased with
probenecid (P < 0.05), whereas allopurinol did not change the FCU in healthy or gouty subjects. FCUs of patients
with gout were lower than the FCUs of healthy subjects (4.8% versus 6.9%; P < 0.0001).
Conclusions: The present studies indicate that the spot-FCU is a convenient, valid, and reliable indicator of the
efficiency of the kidney in removing urate from the blood and thus from tissues. Spot-FCU determinations may
provide useful correlates in studies investigating molecular mechanisms underpinning the observed range of
efficiencies of the kidneys in clearing urate from the blood.
Trial Registration: ACTRN12611000743965
Introduction
Gout is the most prevalent inflammatory arthritis in
men, and its incidence is increasing globally [1]. It is
caused by deposition of monosodium urate monohy-
drate (MSU) crystals in and around joints after long-
standing hyperuricemia. Hyperuricemia is defined as a
plasma urate concentration greater than 0.42 mM and is
the most important risk factor for gout, with the risk
increasing as plasma urate concentrations increase
above this threshold. Hyperuricemia and gout also cor-
relate with risk factors for cardiovascular disease (hyper-
tension, obesity, and diabetes) [2,3].
Urate concentration in the body is governed by dietary
purine intake as well as the endogenous synthesis and
excretion of urate. Overproduction of urate, as a result
of high dietary intake of urate precursors or abnormal
enzymatic synthesis, accounts for hyperuricemia in
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approximately 10% of patients [4]. Approximately two
thirds of urate is renally cleared, with the remainder
secreted into, and metabolized within, the gastrointest-
inal tract [5].
It is generally believed that most hyperuricemia in
subjects with normal glomerular filtration rates results
from a significant inefficiency of the kidneys to clear
urate [6,7]. Urate is filtered at the glomerulus, then
reabsorbed, and is also secreted by the renal tubules [8].
A variety of urate transporters located in the renal
tubules are responsible for the resorption and secretion
of urate [8]. The inefficiency of renal clearance in those
with normal glomerular filtration rates is considered
likely to be the result of impaired tubular secretion,
increased tubular resorption, or a combination of both.
A strong genetic influence on renal clearance of urate
has been identified, with its heritability being reported
as about 87% [9]. To date, however, studies of genetic
polymorphisms of identified urate tubular transporter
genes [10-12] have been unable to account for the
strong genetic influence on the renal clearance of urate.
The fractional clearance of urate (FCU) is the ratio of
renal urate clearance to creatinine clearance, thereby
expressing urate clearance as a fraction of creatinine
clearance. As such, it provides information about the
efficiency of the renal tubular mechanisms of urate
clearance by correcting for the effect of the glomerular
filtration rate, as estimated by the creatinine clearance.
It does not measure the amount of urate excreted by
the kidney. Thus, it has been proposed that the FCU
may be a better correlate than the renal clearance of
urate with which to identify subjects whose kidney
tubules, inherently, are less efficient at clearing urate
from the blood [13].
The FCU has the practical advantage of eliminating
the need for the commonly unreliable timed collection
of urine needed for direct measures of renal clearance
[14-16]. Thus, FCU measurement is potentially more
convenient than directly determining the renal clearance
of urate that conventionally requires a 24-hour urine
collection, in contrast to FCU, which does not require a
timed urine collection.
Although the renal clearance of urate decreases with
decreasing creatinine clearance down to about 30 ml/min,
FCU remains quite stable and increases only marginally
[17]. However, below 30 ml/min, the FCU increases dis-
proportionately [17]. Hence, adjusting the renal clearance
of urate according to creatinine clearance (that is, calculat-
ing the FCU), means that FCU is approximately indepen-
dent of glomerular kidney function for subjects with
reasonable renal function.
FCU can be measured over a period of 24 hours or by
spot measurement of plasma and urine concentrations
of both urate and creatinine, the spot collection being
clearly more convenient. However, the reliability of the
spot method is uncertain, perhaps being less stable at
various times during 24 hours. Therefore, in the present
study, we first examined the reliability of a spot-urine
collection to estimate FCU. Second, we explored the
effect of probenecid (an uricosuric) and allopurinol (a
xanthine-oxidase inhibitor) on FCU values. Third, a spot
FCU was investigated in patients with gout before and
after treatment with allopurinol. Finally, we examined
the distribution of FCU values in healthy volunteers and
in subjects with gout.
Materials and methods
The studies were approved by the St. Vincent’s Hospital
Human Research Ethics Committee (reference numbers:
H05/046, H06/107, 08/SVH/137, 10/093, and 11/SVH/4)
and the University of New South Wales Research Ethics
Committee, in compliance with the Helsinki Declara-
tion. Written informed consent was obtained from all
study participants.
Patients and study design
The study was conducted in three parts: Part 1 (Valida-
tion), Part 2 (Application), and Part 3 (Comparison).
Part 1 was broken up into smaller studies, A to D. All
subjects were aged between 18 and 80 years.
Part 1: Validation
Study 1A: Comparison of spot FCU with timed FCU
over 24 hours Healthy, nonsmoking subjects (n = 12;
seven males) were not permitted alcohol or caffeine for
48 hours and 24 hours, respectively, before the study.
Water intake was controlled at 100 ml/h for the
12-hour daytime period of the study. Subject screening
included a medical history and a clinical examination
followed by routine hematologic and biochemical blood
tests (including plasma creatinine and urate concentra-
tions). A spot-urine sample was provided and was
immediately analyzed for urate and creatinine concen-
trations. The subjects began a 24-hour urine collection
at 2000 hours. This was divided into a series of consecu-
tive, timed collections of urine (12-hour overnight, fol-
lowed by a 2-hour, 4-hour, and 6-hour collection).
Venous blood samples were taken at the midpoint of
the 24-hour period (0800 hours).
Study 1B: Variability of spot FCU: morning compared
with afternoon Healthy, nonsmoking subjects (n = 13;
six males) were not permitted alcohol or caffeine for 48
hours and 24 hours, respectively, before the study. The
subjects provided one blood sample (4 ml) in the morn-
ing, together with morning and afternoon spot samples
of urine on each of the 3 study days with at least 1 day
separating each collection. Subjects were asked to void
on waking in the morning. Consequently, the spot-urine
sample collected in the morning was the second voiding
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of the bladder for that day. The plasma and urine sam-
ples were analyzed for urate and creatinine concentra-
tions. The subjects were encouraged to follow their
normal daily routines throughout the study week,
although alcohol consumption and vigorous exercise
were to be avoided 12 hours and 24 hours, respectively,
before the study days.
Study 1C: Effect of allopurinol and probenecid on
FCU in healthy subjects Data collected previously as
part of an investigation of the interaction between allo-
purinol and probenecid was used for Study C [18]. In
this study, healthy, nonsmoking subjects (n = 11, 3
males) were dosed with allopurinol (A; 150 mg, twice
daily), probenecid (P; 500 mg, twice daily), or allopurinol
plus probenecid (A+P; 150 mg, twice daily, and 500 mg,
twice daily, respectively) for up to 7 days to achieve
steady state concentrations. This was a three-way, cross-
over trial with a 14-day washout period before patients
entered each arm of the study. Eight serial plasma sam-
ples (1, 2, 3, 4, 6, 8, 10, and 12 hours after the morning
dose) and 12-hour urine samples were collected at base-
line (before treatments) and at Day 8 of treatment.
Plasma and urinary creatinine and urate concentrations
were determined. Subjects fasted overnight and avoided
alcohol and caffeinated drinks for 24 hours before each
study day. Complete subject characteristics have been
previously reported [18].
Study 1D: Effect of allopurinol on FCU in patients
with gout Patients with gout (n = 36, 35 males) were
recruited. Twenty-two of these patients had not yet
begun treatment with allopurinol, whereas the remain-
der continued the dose of allopurinol being taken at the
point of study entry. The dose of allopurinol was titrated
incrementally as needed to reduce plasma urate to target
concentrations. Blood and spot-urine samples were col-
lected for determination of plasma and urinary creati-
nine and urate concentrations. This study was registered
in the Australian and New Zealand Clinical Trial Regis-
try (ACTRN12611000743965).
Part 2: Application: Distribution of FCU in healthy subjects
and patients with gout
Eighty-five healthy men recruited to the study provided
a single plasma sample and a random spot-urine sample.
Plasma and urinary creatinine and urate concentrations
were determined from these samples. No restriction was
imposed on daily activities or on diet. Demographic fea-
tures including age, height, weight, and waist circumfer-
ence were recorded.
All data combined from the subjects in Parts 1 and 2
are termed the SVH subjects (n = 154, 118 healthy sub-
jects and 36 subjects with gout). Subjects with data in
more than one study (n = 3) were considered just once
in the grouped SVH subjects cohort. The distribution of
FCU in these groups was examined.
Part 3: Comparisons: comparison with data from the
literature
Data extracted from the literature [7,19-28] were used to
calculate and compare FCU values with those from the
present study.
Sample preparation
Plasma samples from healthy volunteers were frozen
promptly after collection. Within 2 hours of collection,
an aliquot (4 ml) of each urine sample was alkalinized
(1.0 M NaOH, 3 drops) to prevent formation of less-solu-
ble uric acid and stored (-20°C) for reanalysis, if required.
Urate in plasma and urine was measured by using the
uricase method [29], and creatinine, using the Jaffe
method by the Pathology Department (Sydpath) of St.
Vincent’s Hospital Sydney, by using Roche reagents on a
Roche Modular Analyser (Roche Diagnostics Australia,
Castle Hill, NSW).
Data and statistical analysis





÷ Ucreat · V
Pcreat
(1)




Pur · Ucreat (2)
Where U and P represent urinary and plasma concen-
trations, ur is urate, and creat is creatinine. The resul-
tant ratio is expressed as a percentage.
In Study 1A, the FCUs derived from the 24-hour
urine-collection measurements were calculated by sum-
mation of data from the 2-, 4-, 6-, and 12-hour time
periods making up the 24 hours.
Where appropriate, data are presented as the mean
and 95% confidence intervals. A repeated measures,
one-way analysis of variance (ANOVA) with a Bonfer-
roni post hoc analysis was used to examine differences
in FCUs (Study 1A, 1C), and a two-way ANOVA with
repeated measures was used to compare the interday
and intraday FCU (Study 1B). FCUs at various doses of
allopurinol in the gouty population (Study 1C) were
examined with a one-way ANOVA. An unpaired t test
was used to examine the differences in FCUs between
the healthy subjects and the patients with gout (Part 2).
The data were assessed for normality of distribution by
using the D’Agostino-Pearson test. FCU values were
listed in ascending order and normalized by using the
Normdist function in Excel, and the distributions were
graphed. Statistical analyses were conducted by using
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GraphPad (version 5; GraphPad Software, San Diego,
CA, USA) and PASW statistics (version 18.0).
Results
Part 1: Validation
Study 1A: Comparison of spot FCUs with timed FCUs over
24 hours
The mean FCU collected from spot morning urine and
plasma samples was similar (7.4%) to the FCUs deter-
mined from 24-hour collections (6.9%) (Table 1). The
mean FCU of the overnight 12-hour samples was 5.3%.
This was considerably lower than that for the timed col-
lection periods during the day. Intersubject coefficients
of variation (CV) for spot-urine FCUs and 24-hour
urine FCUs were both 28%.
Study 1B: Variation in spot FCUs in mornings and
afternoons
No significant differences were found between morning
and afternoon FCUs, although a trend was noted for
FCUs to be lower in the morning (P = 0.11; 10 subjects
showed lower FCU; Table 2). No difference occurred in
morning or afternoon FCUs between study days. Indivi-
dual FCU values were variable, ranging from 4.3% to
16.5%. Two male subjects (V04 and V08) were hyperuri-
cemic (urate concentration, > 0.42 mM). An outlier
(Table 2, Subject V05 Day 3 afternoon collection) exhib-
ited an unexplained 100% increase in FCU from the
morning to the afternoon collection. The plasma and
spot-urine samples for this subject were reassayed (post-
frozen storage). Less than a 1% variation in urinary
urate was measured in thawed samples stored for 3
weeks at -20°C compared with the freshly analyzed sam-
ples. With Grubb’s test for outliers [30], this value was
excluded from the overall analysis. The within-subject
CV for FCUs was 16.4% (range, 6% to 23%).
Study 1C: Effect of allopurinol and probenecid on FCU in
healthy subjects
At baseline, the mean FCU was 7.9%. Allopurinol did
not significantly change the FCU (7.2%) (Table 3). By
contrast, FCUs increased approximately threefold when
both probenecid and the combination of allopurinol and
probenecid were administered. The effect of the combi-
nation was not significantly different from the effect of
probenecid treatment alone.
Study 1D: Effect of allopurinol on FCUs in patients with
gout
The mean FCU in patients with gout before treatment
with allopurinol (n = 22) was 4.6% (95% CI, 3.8% to
5.4%). Escalation of allopurinol dose did not significantly
alter FCUs for these 22 patients (Figure 1). For the total
gout cohort (n = 36), the mean FCU was 4.8% (95% CI,
4.2% to 5.5%).
Part 2: Application
The mean age of the healthy subjects and gouty
patients was 26 years and 56 years, respectively (range,
16 to 80 years). FCUs were normally distributed in
both healthy subjects (mean FCU ± standard deviation,
6.9% ± 2.1%) and in gouty patients (mean FCU ± SD,
4.8% ± 1.9%). The mean FCU for all healthy normouri-
cemic subjects (n = 110) and hyperuricemic and gouty
subjects combined (eight healthy hyperuricemics and
36 gouty patients), was 7.0% ± 2.0% and 4.9% ± 1.9%,
respectively (Figure 2). This difference was highly sig-
nificant, but a large overlap occurred between the two
groups. Removing 19 women, all of whom were preme-
nopausal, from the 110 healthy normouricemic patients
did not reduce the FCU significantly (from 7.0% ± 2.0%
to 6.9% ± 2.1%). Mean ± SD FCUs for women were
7.2% ± 1.5%.
Table 1 Fractional clearance of urate (%) in healthy subjects derived from timed urine collections within a 24-hour
period
Subject Spot am 12-hour overnight 2-hour 4-hour 6-hour 24-hour
H01 8.0 5.7 9.9 9.7 7.0 7.1
H02 7.1 3.4 9.0 12.6 7.9 6.6
H03 6.3 3.0 10.6 6.8 6.7 4.8
H04 6.3 5.3 8.5 6.0 8.1 6.4
H05 5.2 3.8 5.2 7.1 6.7 5.2
H06 6.3 5.3 8.5 7.9 7.0 6.4
H07 8.4 6.7 14.3 8.1 7.5 7.8
H08 6.4 7.0 9.0 6.9 7.4 7.3
H09 4.3 2.2 3.0 5.1 6.1 3.8
H10 10.7 11.9 15.8 16.4 12.0 11.1
H11 11.3 2.1 7.1 6.3 9.7 5.8
H12 8.8 7.3 8.5 9.5 7.7 7.9
Mean 7.4 5.3a 9.1b 8.5 7.8 6.9b
95% CI 6.1 to 8.8 3.6 to 7.1 6.9 to 11.3 6.5 to 10.6 7.0 to 8.8 5.4 to 8.3
Study 1A, n = 12. Urine collection began at 2000 hours with the 12-hour overnight collection. a Statistically significant difference when compared with other
collection periods (P < 0.05). bStatistically significant difference when compared with each other (P < 0.05).
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Mean FCU ± SD (95% CI) for the eight healthy hyperur-
icemics (plasma concentrations > 0.42 mM), was signifi-
cantly lower than for the 110 healthy normouricemics
[5.3% ± 1.9%, (3.7 to 6.8) versus 7.0% ± 2.0% (6.6 to 7.4)].
Once again, a large overlap occurred between the two
groups.
Part 3: Comparison
Comparison with data from the literature
All FCU values extracted and calculated from the litera-
ture are reported in Table 4. In healthy subjects, the mean
FCU ranged from 6.5% to 12.8%. Female patients had
higher FCU values than did male patients. Subjects with
gout had a lower FCU value than did healthy subjects. The
FCUs from the SVH cohort were within the ranges of
FCUs reported for healthy subjects from the literature.
However, comparisons were very difficult because classifi-
cation of underexcretion, normoexcretion, and overpro-
duction differed markedly between authors (Table 4).
Discussion
The renal clearance of urate examines the efficiency of
the removal of urate by the kidneys by all mechanisms
available to the kidney, whereas the FCU examines the
efficiency of the kidneys to remove urate relative to the
creatinine clearance. Thus, FCU differs from the rate of
Table 2 Fractional clearance of urate (%) in healthy subjects in the morning and afternoon on three separate study
days
Subject Day 1 am Day 2 am Day 3 am Day 1 pm Day 2 pm Day 3 pm Mean
V01 7.8 8.1 8.5 6.8 6.6 7.7 7.6
V02 6.1 8.8 6.9 8.8 11.4 9.7 8.6
V03 9.7 8.1 4.8 8.5 10.4 7.6 8.2
V04 4.2 4.9 4.8 3.4 3.8 4.9 4.4
V05 10.6 7.5 8.1 10.0 9.9 16.5 10.5
V06 8.8 7.6 6.7 7.8 7.9 7.6 7.7
V07 7.3 8.1 11.0 8.5 9.0 10.6 9.1
V08 5.7 5.0 6.3 6.7 5.5 8.0 6.2
V09 5.9 4.3 4.2 6.1 4.2 6.7 5.2
V10 6.4 6.3 7.6 9.5 9.8 9.7 8.2
V11 8.9 9.0 9.8 10.2 8.9 10.0 9.5
V12 6.7 6.5 9.9 7.9 7.9 8.9 8.0
V13 8.7 7.8 6.7 4.8 8.3 7.0 7.2
Mean 7.4 7.1 7.3 7.6 8.0 8.9 7.7
95% CI 6.3 to 8.5 6.2 to 8.0 6.1 to 8.6 6.4 to 8.8 6.5 to 9.4 7.1 to 10.5 6.7 to 8.7
Study 1B; n = 13. Mean age (range) was 35.1 (21 to 73) years.
Table 3 The effect of allopurinol, probenecid, and the
combination on fractional clearance of urate in healthy
subjects
Subject FCU (%)
Baseline A P A + P
H01 4.5 5.7 8.3 14.9
H02 8.1 8.5 25.9 24.1
H03 12.1 7.9 34.0 33.4
H04 4.8 5.4 22.6 26.2
H05 8.2 7.4 22.9 31.7
H06 10.2 10.0 23.1 21.5
H07 5.3 3.9 19.6 23.8
H08 2.5 5.8 16.2 21.4
H09 11.5 10.3 27.4 22.1
H10 12.5 7.5 30.8 30.1
H11 7.5 6.4 17.5 22.9
Mean 7.9 7.2 22.6 24.7
95% CI 5.7 to 10.2 5.8 to 8.5 17.8 to 27.4 21.1 to 28.3
Study 1C; n = 11. A, allopurinol; P, probenecid; A + P, the combination. Mean
age (range) was 24 (21 to 36) years.
Figure 1 Fractional clearance of urate CU in gouty patients
with incrementally increased doses of allopurinol to achieve
target concentrations (Study 1D). Mean age (range) was 56 years
(17 to 80 years) (n = 22). The number of patients at each dose level
is indicated on the graph.
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renal excretion of urate, which examines the amount of
urate removed by the kidneys per unit time. Hence, the
term fractional “clearance” of urate (FCU) is perhaps a
more accurate descriptor of the ratio of clearance of
urate to creatinine than the alternative term sometimes
used, the fractional “excretion” of urate [16,28].
The present study established that the FCU could be
derived from a spot-urine sample, thereby overcoming
some of the uncertainties around the inconvenient and
commonly unreliable 24-hour urine collection [15,16], as
well as providing a tool to examine more readily the
renal tubular urate transport. FCU was unaltered by allo-
purinol but increased when probenecid was adminis-
tered, both outcomes being consistent with the accepted
mechanism of the action of these drugs (inhibition of
urate synthesis by the former and, inhibition of tubular
reuptake of urate by urate anion transporter 1 (URAT1)
by the latter [31]).
The FCU was marginally higher in the afternoon than
in the morning. This difference probably reflects diurnal
rhythms in renal function. Vahlensieck et al. [32]
showed that urinary urate concentrations are highest
between 11 a.m. and 5 p.m., and urinary concentrations
of creatinine exhibit similar circadian variation [33]. In
addition, the low FCU seen at night may be due to the
relative dehydration associated with activation of the
renin-angiotensin system [13].
The FCU has not been examined widely in studies on
urate, although it has been used in heritability studies in
twins [9] and correlations on the handling of urate in
gouty patients and their relatives [34]. A significant
association has been found between a low FCU (≤6.6%)
and SLC2A9 variants [11], and thus highlights the
potential of the FCU in understanding the function of
SNPs in other urate transporters.
In our study, although the FCU was generally greater
in women than men, statistical differences were not
observed because of the small numbers of healthy
female subjects in our studies. This contrasts with the
literature, in which the FCU was statistically higher in
women [26]. Women are known to have lower plasma
concentrations of urate because of the uricosuric effect
Figure 2 Distribution of fractional clearance of urate in healthy
and gouty subjects in the SVH cohort (Part 2).
Table 4 FCU values in percentage (mean ± SD) extracted and calculated from the literature in healthy and gouty
subjects




[19] - - - 5.4 ± 1.0 (5) 6.8 ± 1.6 (8)
[20] 6.9 (36) - 4.5 (78) 6.0 (46) -
[21] - - 4.3 (26) - 5.8 (23)
[22] 6.5 ± 2.5 (5) - - - -
[23] 9.9 ± 1.5 (9) - - - -
[24] 7.0 ± 1.6 (7) - - 5.8 ± 1.3 (10) 8.7 ± 2.7 (6)
[25] 6.9 ± 1.3 (10) 5.1 ± 1.9 (11) - - -
[7] 7.9 ± 3.0 (41)
4.4 ± 1.4
(11 hyperuricemic)




- - - -




- - - -
[28] 7.6 ± 1.9 (72) 4.6 ± 1.2 (100) - - -
FCU, fractional clearance of urate. Definitions of excretor phenotype as described by respective authors (expressed as percentage per 1.73 m2 body-surface area,
where possible). Underexcretion, urinary urate < 826 mg/day/1.73 m2 [20]; urate clearance < 6 ml/min/1.73 m2 [21]. Normoexcretion, urinary urate < 720 mg/day/
1.73 m2 [19]; > 830 mg/day/1.73 m2) [20]; urate clearance, > 6 ml/min/1.73 m2 [21]; urinary urate < 700 mg/day/1.73 m2 [24]. Overproduction, urinary urate > 720
mg/day/1.73 m2 [19]; > 700 mg/day/1.73 m2 [24].
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of estrogen [35], and hence, the incidence of gout is
lower in pre- than postmenopausal women [36].
FCU values are available from the literature in both
healthy and hyperuricemic/gouty subjects (Table 4),
although FCU has generally not been emphasized in such
studies. In some cases, only the renal clearances of urate,
creatinine, or inulin (marker of glomerular function)
were reported, and we have calculated the FCU from
these data sets. The present studies also showed that the
FCU values were normally distributed, contrasting with a
previous study that reported a log normal distribution in
healthy subjects [37]. Our results on FCU are consistent
with previous data, whereby patients with gout, on aver-
age, have a lower FCU than do those without gout.
Healthy hyperuricemic patients (that is, without gout)
had a lower FCU compared with normouricemic patients,
this being in line with the findings of Lang et al. [7],
whereby the mean FCU of hyperuricemic patients was
significantly lower than that of normouricemic patients
(4.9% versus 7.0%). It must be noted that gout is largely
believed to be related to an inefficient renal clearance of
urate, and only in a minority of patients is it due primar-
ily to overproduction of urate. However, some patients
with an apparent overproduction, based on the amount
of urate secreted in their 24-hr urinary collection output,
may also have inefficient renal clearance of urate [28].
A reduced FCU was previously reported in other dis-
ease states, including familial juvenile hyperuricemic
nephropathy, prerenal azotemia, and idiopathic uric acid
nephrolithiasis [24,38-43]. However, a low FCU is not
diagnostic of a disease state per se, because healthy nor-
mouricemic patients with a low FCU are not uncommon,
as seen in the present study. Despite a relatively low
FCU, many are able to maintain a normal plasma urate,
perhaps because of relatively low synthesis of urate.
Hyperuricemia was also detected in a small number of
healthy subjects with normal FCUs. The clinical implica-
tion of a low FCU in an otherwise healthy individual is
not known; however, we suggest that these individuals
might be more susceptible subsequently to develop
hyperuricaemia and gout, especially if their dietary intake
of urate precursors is relatively high.
Finally, FCU is not currently proposed for routine clini-
cal use; rather, especially the spot test can be used as a
tool in studies exploring the basis for variations in renal
handling of urate, including epidemiologic investigations.
Conclusions
FCU derived from a spot, daytime urine sample is a
valid method to provide an estimate of FCU, not differ-
ent from the FCU estimated by using the traditional
24-hour urine collection. The precision of the spot FCU
is comparable to that of other urine-based biochemical
tests. Patients with gout have, on average, a lower FCU
compared with healthy patients, but considerable
overlap exists, and the FCU alone is not predictive of
hyperuricemia. A low FCU may be a risk factor for sub-
sequent development of hyperuricemia. Spot FCU may
facilitate studies of the renal mechanisms contributing
to hyperuricemia.
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